Amnio Technology was founded in 2012 and is focused on optimizing the regenerative potential and clinical use of amniotic tissue.
PalinGen® products do not require fetal sacrifice and recovery is performed with maternal consent during elective Cesarean delivery.
Manufacture of PalinGen® Membrane, Hydromembrane, XPlus Membrane, and XPlus Hydromembrane.
Amnio Technology is committed to Compliance, Quality and fosters a culture of Continuous Improvement. Amnio Technology has a core competency in Current Good Tissue Practices (cGTP). Our products meet or exceed the Quality and donor testing expectations set by the FDA in 21 CFR 1271. All Amnio Technology Products are manufactured in an FDA Registered and American Association of Tissue Banks (AATB) accredited facility.
Amnio Technology enhances the gift of human birth tissue donation by developing, processing and distributing innovative allografts that provide regenerative therapies to improve quality of life.
Amnio Technology is committed to advancing the science of regenerative medicine by developing and introducing new amniotic tissue allografts and technologies to treat patients in need.
An industry leader in the development and manufacture of amnion-derived technologies
Copyright © 2024 Amnio Technology, LLC